Lion Biotechnologies Inc
Lion Biotechnologies Inc operates in various business sectors.
Lion Biotechnologies Inc (2LB) - Net Assets
Latest net assets as of June 2024: €768.54 Million EUR
Based on the latest financial reports, Lion Biotechnologies Inc (2LB) has net assets worth €768.54 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€964.32 Million) and total liabilities (€195.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €768.54 Million |
| % of Total Assets | 79.7% |
| Annual Growth Rate | 4.63% |
| 5-Year Change | 95.54% |
| 10-Year Change | N/A |
| Growth Volatility | 55.03 |
Lion Biotechnologies Inc - Net Assets Trend (2018–2023)
This chart illustrates how Lion Biotechnologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lion Biotechnologies Inc (2018–2023)
The table below shows the annual net assets of Lion Biotechnologies Inc from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €584.61 Million | +17.01% |
| 2022-12-31 | €499.64 Million | -19.63% |
| 2021-12-31 | €621.66 Million | -5.31% |
| 2020-12-31 | €656.50 Million | +119.59% |
| 2019-12-31 | €298.97 Million | -35.87% |
| 2018-12-31 | €466.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lion Biotechnologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 163961500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.60 Billion | 444.22% |
| Total Equity | €584.61 Million | 100.00% |
Lion Biotechnologies Inc Competitors by Market Cap
The table below lists competitors of Lion Biotechnologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Equals Group PLC
LSE:EQLS
|
$34.33K |
|
Brinno Incorporated
TWO:7402
|
$34.34K |
|
RED ROBIN GRMT BURG
BE:RRN
|
$34.35K |
|
BONTERRA ENERGY (QNC1.SG)
STU:QNC1
|
$34.36K |
|
IMPREGILO
BE:IPJ1
|
$34.31K |
|
208850
KO:208850
|
$34.31K |
|
Beeio Honey Ltd
TA:BHNY
|
$34.30K |
|
Chokwang Paint Co. Ltd.
KQ:004910
|
$34.30K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lion Biotechnologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 499,638,000 to 584,613,000, a change of 84,975,000 (17.0%).
- Net loss of 444,037,000 reduced equity.
- New share issuances of 463,281,000 increased equity.
- Other factors increased equity by 65,731,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-444.04 Million | -75.95% |
| Share Issuances | €463.28 Million | +79.25% |
| Other Changes | €65.73 Million | +11.24% |
| Total Change | €- | 17.01% |
Book Value vs Market Value Analysis
This analysis compares Lion Biotechnologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.92x to 1.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €3.78 | €3.49 | x |
| 2019-12-31 | €2.37 | €3.49 | x |
| 2020-12-31 | €4.47 | €3.49 | x |
| 2021-12-31 | €3.96 | €3.49 | x |
| 2022-12-31 | €2.66 | €3.49 | x |
| 2023-12-31 | €2.28 | €3.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lion Biotechnologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -37345.42%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.33x
- Recent ROE (-75.95%) is below the historical average (-59.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -26.51% | 0.00% | 0.00x | 1.03x | €-170.20 Million |
| 2019 | -82.17% | 0.00% | 0.00x | 1.15x | €-275.57 Million |
| 2020 | -39.54% | 0.00% | 0.00x | 1.17x | €-325.23 Million |
| 2021 | -55.05% | 0.00% | 0.00x | 1.25x | €-404.42 Million |
| 2022 | -79.24% | 0.00% | 0.00x | 1.33x | €-445.86 Million |
| 2023 | -75.95% | -37345.42% | 0.00x | 1.33x | €-502.50 Million |
Industry Comparison
This section compares Lion Biotechnologies Inc's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.